Helsinn Healthcare S.A.: ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
Not intended for US media
Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, Helsinn ) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara; ONO ) announced today that ONO received the manufacturing and marketing approval of Adlumiz (generic name: anamorelin hydrochloride) Tablet 50mg ( Adlumiz ), a ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan.
Helsinn Healthcare S.A.
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
Not intended for US media
Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara; “ONO”) announced today that ONO received the manufacturing and marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”), a ghrelin receptor agonist, for the treatment of cancer cachexia in malignan
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) and Ono Pharmaceu.